Insights & news

Results of Annual Regulatory Dialogue between European Commission, European Medicines Agency and US Food and Drug Administration

  • 23/06/2020
  • Articles

Senior officials of the European Commission, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) held their annual regulatory dialogue on 18 June and 19 June 2020 (see, attached EMA press release of 22 June 2020). While the EMA and the FDA say to have “almost daily” interactions, the annual meetings are designed to review ongoing initiatives and define strategic priorities for the coming years.
 
The three agencies discussed (i) the development, review and availability of Covid-19 vaccines; (ii) possible cooperation on individualised or bespoke therapies for ultrarare diseases; (iii) the compiling of real world evidence (observational research in Covid-19 will serve as a model); (iv) orphan and pediatric medicines; and (v) the expansion of the scope of the mutual recognition agreement (MRA) of good manufacturing practice to veterinary medicines and possibly human vaccines and plasma-derived medicinal products (the first full implementation of the MRA for a range of specific human medicines was completed in July 2019 – see, Van Bael & Bellis Life Sciences News Alert of 12 July 2019).

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *